hVIVO (LON:HVO) Trading 13% Higher – Should You Buy?

hVIVO plc (LON:HVO)’s share price traded up 13% during trading on Tuesday . The company traded as high as GBX 8 ($0.11) and last traded at GBX 7.80 ($0.10). 9,588,585 shares traded hands during mid-day trading, an increase of 223% from the average session volume of 2,969,923 shares. The stock had previously closed at GBX 6.90 ($0.09).

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Shore Capital dropped their price objective on hVIVO from GBX 35 to GBX 25 and set a “buy” rating on the stock in a research note on Tuesday, September 23rd. Peel Hunt reiterated an “add” rating and issued a GBX 21 price objective on shares of hVIVO in a research note on Tuesday, July 29th. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of GBX 23.

hVIVO Stock Up 2.4%

The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The stock has a market capitalization of £54.91 million, a P/E ratio of 1,037.66 and a beta of 0.97. The firm has a 50 day moving average of GBX 9.24 and a 200-day moving average of GBX 11.96.

hVIVO (LON:HVO) last issued its quarterly earnings results on Tuesday, September 23rd. The company reported GBX (0.29) earnings per share (EPS) for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. On average, equities research analysts expect that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.